This occurs because the medication directly addresses insulin resistance -a core problem in pre-diabetes-by boosting the bodys sensitivity to insulin
Proceedings of the National Academy of Sciences of the United States of America 94, 10925-10930CrossRefGoogle ScholarPubMed 44Yachie, A., Niida, Y., Wada, T
Have you considered sending thumb drives instead
Sodium-glucose co-transporter 2 inhibitors in nonalcoholic fatty liver disease
The trial program has evolved from glycemic-safety and outcomes studies in T2D (the LEADER, SUSTAIN-6, REWIND, EXSCEL, and PIONEER 6 era [10][13], [19]), to outcomes trials in expanded populations including obesity without diabetes (SELECT [3]), HFpEF with obesity (SUMMIT [5], with a companion semaglutide program in STEP-HFpEF [20], [21]), CKD (FLOW [22]), and an active-comparator setting (SURPASS-CVOT [6])
,